Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Small Cell Lung Carcinoma 9Breast Neoplasms 8Triple Negative Breast Neoplasms 2Lung Neoplasms 2Carcinoma, Neuroendocrine 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neutropenia 1Neoplasm Metastasis 1Intracranial Germ Cell CNS Tumor, Childhood 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Small Cell 1Carcinoma, Pancreatic Ductal 1

Interventions

pegfilgrastim 30Filgrastim 29Cyclophosphamide 10Docetaxel 8pegylated granulocyte colony-stimulating factor 7Etoposide 7Cytarabine 7Ciprofloxacin 5Cefepime 5eflapegrastim 4Vancomycin 4Leucovorin 4Granulocyte Colony-Stimulating Factor 4Fluorouracil 4Doxorubicin 4Peripheral Blood Stem Cell Transplantation 3Mitoxantrone 3Methotrexate 3Levofloxacin 3Irinotecan 3Idarubicin 3Daunorubicin 3Cyclosporine 3Caspofungin 3Carboplatin 3trifluridine tipiracil drug combination 2plerixafor 2liposomal amphotericin B 2Vincristine 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neutropenia × EC regimen × Clear all
NCT02527746 2024-02-23

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

EVIVE Biotechnology

Phase 1 Completed
18 enrolled 22 charts
Breast

Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡